Author:

Keywords:

Administration, Inhalation, Adrenergic beta-2 Receptor Agonists, Aged, Double-Blind Method, Drug Combinations, Female, Fluticasone Propionate, Salmeterol Xinafoate Drug Combination, Glucocorticoids, Glycopyrrolate, Humans, Indans, Male, Middle Aged, Muscarinic Antagonists, Pulmonary Disease, Chronic Obstructive, Quinolones, Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, OBSTRUCTIVE PULMONARY-DISEASE, TO-SEVERE COPD, INHALED CORTICOSTEROIDS, BLOOD EOSINOPHILS, PARALLEL-GROUP, LUNG-FUNCTION, DOUBLE-BLIND, EXACERBATIONS, EFFICACY, SAFETY, Fluticasone-Salmeterol Drug Combination, FLAME Investigators, 11 Medical and Health Sciences, 32 Biomedical and clinical sciences, 42 Health sciences

Abstract:

Most guidelines recommend either a long-acting beta-agonist (LABA) plus an inhaled glucocorticoid or a long-acting muscarinic antagonist (LAMA) as the first-choice treatment for patients with chronic obstructive pulmonary disease (COPD) who have a high risk of exacerbations. The role of treatment with a LABA-LAMA regimen in these patients is unclear.